Clostridium difficile Infections: Diagnosis, Treatment, and Prevention
Comparative Effectiveness of Standard Antibiotic Treatment for CDI
The target patient population was of adult patients with clinical signs consistent with CDI in hospital, outpatient, or long-term care settings. Studies that examined the comparative effectiveness of the antimicrobial treatments by organism strain were included. The interventions that were included consisted of vancomycin, metronidazole, bacitracin, nitazoxanide, rifaximin, fidaxomicin, and rifampin. As fusidic acid and teicoplanin are not currently approved for use in the United States, these treatments were excluded. Fidaxomicin was added as an intervention because FDA approval was granted May, 2011. Desired outcomes included initial cure, recurrence (variably defined by symptoms with or without a positive test for C. difficile), and mortality, which are outcomes of interest to clinicians and are reported in most studies. Also included were time to resolution of diarrhea, which may be important because of effects on patient comfort, duration of hospitalization, and for infection control purposes. Reported harms data to patients using any of the standard antimicrobial treatments were also included.
- Dudley MN, McLaughlin JC, Carrington G, et al. Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial. Arch Intern Med 1986 Jun; 146(6):1101–4.
- Fekety R, Silva J, Kauffman C, et al. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989 Jan; 86(1):15–9.
- Keighley MR, Burdon DW, Arabi Y, et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. BMJ 1978 Dec 16; 2(6153):1667–9.
- Lagrotteria D, Holmes S, Smieja M, et al. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin Infect Dis 2006 Sep 1; 43(5):547–52.
- Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011 Feb 3; 364(5):422-31.
- Musher DM, Logan N, Bressler AM, et al. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis 2009 Feb 15; 48(4):e41–6.
- Musher DM, Logan N, Hamill RJ, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006 Aug 15; 43(4):421–7.
- Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 1983 Nov 5; 2(8358):1043–6.
- Wenisch C, Parschalk B, Hasenhundl M, et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996 May; 22(5):813–8.
- Young GP, Ward PB, Bayley N, et al. Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterol 1985 Nov; 89(5):1038–45. Available at: http://www.ncbi.nlm.nih.gov/pubmed/4043661.
- Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007 Aug 1; 45(3):302–7.
Your slide tray is being processed.